查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715701

抗减肥药市场按治疗类型、药物类型、给药途径、剂型、最终用户和分销管道划分－2025-2030 年全球预测

Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年抗减肥药市场价值将达到 107.9 亿美元，2025 年将成长至 116.9 亿美元，复合年增长率为 8.59%，到 2030 年将达到 177 亿美元。

主要市场统计数据
基准年2024年 107.9亿美元
预计2025年 116.9亿美元
预测年份 2030 177亿美元
复合年增长率（%） 8.59%

抗减肥药领域正在经历重大变革，重新关注创新治疗和综合医疗保健策略。最近的进展凸显了对这种影响全球数百万人的疾病的有效治疗方案和程序的重要性。由于肥胖仍然是一个主要的公共卫生问题，对治疗性介入研发的大量投资正在推动着充满活力的市场环境。

该分析提供了治疗领域的整体情况，融合了临床创新、以患者为中心的方法和市场趋势。药物配方和外科手术干预的最新进展反映了抗肥胖解决方案范围的不断扩大。随着政府和私人相关人员优先考虑健康和预防性医疗保健，市场正在转向有针对性的个人化治疗方案。包括医疗保健专业人士、投资者和政策制定者在内的相关人员越来越多地寻求数据主导的洞察力，以便清楚地了解当前的实践和未来的机会。以下部分说明探讨治疗领域的变革性变化、详细的细分见解、区域市场动态以及在这一关键领域运作的主要企业的策略前景。

本报告既是一份指南，也是一份号召，呼吁人们接受重新定义患者照护的融合趋势。持续的科学进步动力，加上务实的监管调整和消费者需求，为抗肥胖治疗市场带来重大变革奠定了基础。

改变抗减肥药市场

近年来，抗减肥药的环境发生了巨大变化。技术创新、更深入的临床见解和不断变化的患者需求的融合正在推动治疗方法的根本转变。药物开发和精准医疗的进步为更有效、更有针对性的治疗方法铺平了道路。市场正在见证传统医疗疗法与创新外科手术干预的结合，从而製定出针对复杂患者特征的综合治疗计划。

法律规范的变化和医学研究投资的增加进一步加速了这些变化。新的临床试验、长期疗效的可靠数据以及製药公司之间的策略伙伴关係正在为新的治疗途径铺平道路提供强大的力量。随着市场参与企业适应这些变化，他们更加重视改善患者的治疗效果、成本效益和安全性。这种演变正在推动相关人员之间的竞争差异化和合作倡议。

此外，数位健康和​​数据分析的进步使得个人化治疗轨迹成为可能，因此患者能够根据即时资讯和循证指南获得最合适的治疗性介入。随着情势的不断发展，相关人员正在利用新趋势不仅满足当前的临床需求，而且应对未来的市场挑战。该领域的发展势头正支撑着一个充满希望的成长和创新时期，为抗肥胖药物的下一个突破奠定了基础。

推动市场动态的关键细分洞察

精心设计的细分框架为抗减肥药市场的分析提供了支撑，深入了解了关键的市场动态。根据治疗类型进行细分，将市场分为药物和治疗方法。同时，药物治疗类别包括布丙酮-纳曲酮、Liraglutide、奥利司他、芬特明-托吡酯、Semaglutide和替泽帕肽等化合物，每种化合物都对治疗结果做出了独特的贡献。同时，治疗方法类别深入研究可调节胃束带、内视镜袖状胃成形术和胃绕道手术等程序干预，为体重管理提供独特的临床方法。

与治疗类型平行，基于药物类型的细分区分非处方药和处方药。这种区别对于理解消费行为和监管的影响起着重要作用。进一步检查给药途径，可以发现两种不同的类别：口服，以胶囊和锭剂为特征；非肠道给药，包括静脉注射和皮下给药。每种给药途径都有不同的临床考虑因素，会影响患者的依从性和治疗效果。

此外，按剂型进行市场细分（区分液体、半固态和固态）可以深入了解产品稳定性和输送机制。根据最终用户细分，市场分为门诊手术中心、医院和专科诊所，突显了实施这些手术的环境的多样性。最后，基于通路的评估，包括医院和诊所药局、网路药局和零售药局的作用，揭示了可以增强市场竞争力的通路和商业策略。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 缺乏运动导致久坐的生活方式
      • 肥胖及相关疾病的发生率不断上升
      • 提高新药的疗效和安全性
    • 限制因素
      • 对抗减肥药副作用的担忧
    • 机会
      • 正在进行的临床试验和研发活动
      • 加大研发投入将推动尖端抗肥胖药物技术的进步
    • 任务
      • 缺乏一致的全球肥胖治疗政策
  • 市场区隔分析
    • 治疗类型：抗减肥药因其有效性而越来越受到青睐。
    • 最终用户：医院扩大抗减肥药的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 抗减肥药市场（依治疗类型）

  • 製药
    • 布丙酮-纳曲酮
    • Liraglutide
    • 奥利司他
    • 芬特明-托吡酯
    • Semaglutide
    • 替泽帕肽
  • 治疗
    • 可调式胃束带手术
    • 内视镜袖状胃成形术
    • 胃绕道手术

第七章 抗减肥药市场（依药物类型）

  • 非处方药
  • 处方药

第八章 抗减肥药市场（依给药途径）

  • 口服途径
    • 胶囊
    • 药片
  • 肠外给药
    • 静脉
    • 皮下

第九章 抗减肥药市场（以药物剂型）

  • 液体剂型
  • 半固态剂型
  • 固态剂型

第十章 抗减肥药市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第 11 章 抗减肥药市场（依通路）

  • 医院/诊所药房
  • 网路药局
  • 零售药局

12. 美洲抗减肥药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区抗减肥药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14.欧洲、中东和非洲抗减肥药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Alizyme PLC
  • Amgen Inc.
  • Arena Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • FlaxoSithKline plc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Nalpropion Pharmaceuticals Inc.
  • Norgine BV
  • Novartis AG
  • Novo Nordisk A/S
  • Orexigen Therapeutics Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi SA
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market was valued at USD 10.79 billion in 2024 and is projected to grow to USD 11.69 billion in 2025, with a CAGR of 8.59%, reaching USD 17.70 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.79 billion
Estimated Year [2025] USD 11.69 billion
Forecast Year [2030] USD 17.70 billion
CAGR (%) 8.59%

The anti-obesity therapeutics sector has undergone remarkable evolution, placing new emphasis on innovative treatments and comprehensive healthcare strategies. Recent advancements have elevated the importance of effective treatment options and procedures in addressing a condition that affects millions globally. As obesity continues to be a leading public health concern, significant investment in research and development for therapeutic interventions has driven a dynamic market environment.

This analysis provides a holistic perspective on the therapeutic landscape, weaving together clinical innovations, patient-centric approaches, and market trends. Recent improvements in drug formulations and surgical interventions reflect the broadening scope of anti-obesity solutions. With governments and private stakeholders prioritizing wellness and preventative care, the market is moving toward targeted and personalized regimens. Stakeholders, including healthcare professionals, investors, and policy makers, are increasingly seeking data-driven insights that offer a clear view of both current practices and future opportunities. The following sections offer an in-depth exploration of transformative shifts in the therapeutic sphere, detailed segmentation insights, regional market dynamics, and strategic perspectives from leading companies operating in this important space.

This report serves as both a guide and a call to embrace the converging trends that are redefining patient care. The ongoing commitment to scientific advancement, in conjunction with pragmatic regulatory adjustments and consumer demand, sets the stage for significant disruption in the anti-obesity treatment market.

Transformative Shifts in the Therapeutics Landscape

In recent years, transformative shifts have redefined the anti-obesity therapeutics landscape. The convergence of technological innovation, deeper clinical insights, and evolving patient needs has spurred a fundamental transformation in therapeutic approaches. Advancements in drug development and precision medicine have paved the way for more efficacious and tailored treatment modalities. The market is witnessing the synthesis of traditional pharmacotherapy with innovative surgical interventions, allowing for integrated treatment plans that address complex patient profiles.

Shifts in regulatory frameworks and increased investments in medical research have further accelerated these changes. New clinical trials, robust data on long-term efficacy, and strategic partnerships among pharmaceutical companies are instrumental in forging novel pathways for treatment. As market participants adapt to these transformative changes, there is a heightened emphasis on patient outcomes, cost-effectiveness, and improved safety profiles. This evolution is driving both competitive differentiation and collaborative initiatives among stakeholders.

Moreover, advancements in digital health and data analytics are enabling personalized treatment trajectories, ensuring that patients receive the most appropriate therapeutic intervention based on real-time information and evidence-based guidelines. As the landscape continues to evolve, stakeholders are leveraging emerging trends to meet not only current clinical demands but also future market challenges. The sector's forward momentum underpins a promising era of growth and innovation, setting the stage for the next breakthrough in anti-obesity care.

Key Segmentation Insights Driving Market Dynamics

An elaborate segmentation framework underpins the analysis of the anti-obesity therapeutics market, which provides a granular understanding of key market dynamics. The segmentation based on treatment type dissects the market into medications and treatments. On one hand, the medications category incorporates a spectrum of compounds including Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide; each contributing uniquely to therapeutic outcomes. On the other hand, the treatments category delves into procedural interventions such as Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery, which offer distinct clinical approaches to weight management.

Parallel to treatment types, segmentation based on drug type distinguishes between over-the-counter and prescription drugs. This differentiation plays a crucial role in understanding consumer behavior and regulatory impacts. Further exploration into the route of administration reveals two distinct categories: the oral route, characterized by capsules and tablets, and parenteral administration, which encompasses both intravenous and subcutaneous methods. Each route embodies different clinical considerations, impacting patient compliance and therapeutic effect.

Additionally, market segmentation by drug formulation, which differentiates among liquid, semi-solid, and solid dosage forms, provides insights into product stability and delivery mechanisms. End-user segmentation categorizes the market among ambulatory surgical centers, hospitals, and specialty clinics, highlighting the diverse environments where these treatments are administered. Finally, an evaluation based on distribution channels-including the roles of hospitals and clinics pharmacies, online pharmacies, and retail pharmacies-sheds light on accessibility and commercial strategies that drive market competitiveness.

Based on Treatment Type, market is studied across Medications and Treatments. The Medications is further studied across Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide. The Treatments is further studied across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery.

Based on Drug Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Route Of Administration, market is studied across Oral Administration and Parenteral Administration. The Oral Administration is further studied across Capsules and Tablets. The Parenteral Administration is further studied across Intravenous and Subcutaneous.

Based on Drug Formulation, market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms.

Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.

Based on Distribution Channel, market is studied across Hospitals & Clinics Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Market Insights Shaping Future Strategies

Geographic analysis of the anti-obesity therapeutics market reveals varied trends and challenges across key regions. In the Americas, robust healthcare infrastructures coupled with high patient awareness are fueling demand for both pharmacological and surgical weight management solutions. The region's dynamic regulatory environment encourages innovation and shortens development timelines, thereby accelerating product launches and market penetration. Meanwhile, in Europe, the Middle East and Africa, there is an increasing inclination towards integrating public health initiatives with privately funded research, fostering an environment of balanced growth and improved patient care. Regulatory reforms and cross-border collaborations in these areas are further enhancing market forecasts.

In the Asia-Pacific region, a rapidly expanding middle-class coupled with growing obesity rates is creating new market opportunities for both traditional therapeutics and novel intervention strategies. Economic improvements and changes in lifestyle have heightened demand for accessible, effective treatment options, resulting in an evolving landscape that is both competitive and innovative. The interplay of cultural nuances, healthcare policies, and distribution channel efficiencies has driven region-specific strategies, prompting market players to tailor their products and services to meet local needs effectively.

These regional insights provide strategic guidance for firms planning global expansion, enabling them to align their offerings with the unique healthcare dynamics and market demands of each target area.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies and Their Strategic Movements

The competitive landscape in the anti-obesity therapeutics market is characterized by the presence of several influential players who are setting the pace for innovation and market growth. Leading companies such as Alizyme PLC, Amgen Inc., and Arena Pharmaceuticals Inc. are actively leveraging research breakthroughs to enhance product pipelines and expand their portfolio of therapeutics. These firms work in collaboration with other prominent industry names like Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and Currax Pharmaceuticals LLC to drive forward advanced treatment protocols.

Other key players, including Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and FlaxoSithKline plc., continue to invest significantly in clinical trials aimed at validating the efficacy and safety of novel therapeutics. Strategic moves by companies such as GlaxoSmithKline PLC, Johnson & Johnson Services Inc., and Merck & Co. Inc. have underlined the market's trend toward increased precision and patient-centric care. Meanwhile, firms like Nalpropion Pharmaceuticals Inc., Norgine B.V., Novartis AG, and Novo Nordisk A/S have identified niche areas within the market to capture unmet needs, further catalyzing competitive dynamics.

Orexigen Therapeutics Inc., Pfizer Inc., Rhythm Pharmaceuticals, Inc., Sanofi S.A., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, Vivus Inc., and Zydus Lifesciences Limited have all executed strategic initiatives that extend beyond traditional drug development to encompass innovative product delivery methodologies and integrated service platforms. The cumulative effect of these strategic movements underscores a market in which both collaborative endeavors and competitive differentiation coexist, providing a fertile environment for sustainable growth.

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alizyme PLC, Amgen Inc., Arena Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, FlaxoSithKline plc., GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck & Co. Inc., Nalpropion Pharmaceuticals Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Orexigen Therapeutics Inc., Pfizer Inc., Rhythm Pharmaceuticals, Inc., Sanofi S.A., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, Vivus Inc., and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to embrace several key strategies to optimize their positioning in the anti-obesity therapeutics market. First, it is essential to invest in robust research and development programs that not only focus on improving existing products but also explore new therapeutic modalities. Emphasizing innovation through clinical trials and multi-disciplinary collaborations can lead to breakthroughs that significantly differentiate market offerings.

Second, aligning product portfolios with evolving regulatory standards and patient preferences will be crucial. Organizations should fine-tune their segmentation strategies to cater to diverse treatment options, drug types, and routes of administration. This targeted focus will enhance market penetration by addressing specific needs across both over-the-counter and prescription segments and by optimizing product formulations.

Third, establishing strategic partnerships with healthcare providers and distribution channels, such as hospitals, specialty clinics, and online pharmacies, can greatly expand market access and improve patient engagement. It is also advisable to leverage digital technologies and data analytics to streamline operations and tailor treatment approaches based on real-time insights.

Finally, fostering a customer-centric approach that emphasizes outcomes and cost-effectiveness is imperative. By continuously monitoring market trends and investing in proactive marketing initiatives, industry leaders can bolster their competitive edge and secure long-term growth in an increasingly dynamic healthcare environment.

Concluding Perspectives on Market Opportunities

In conclusion, the anti-obesity therapeutics market is characterized by its rapid evolution and the emergence of a wide array of advanced therapies. The integration of novel drug formulations, dynamic treatment procedures, and a robust focus on targeted patient outcomes underpins the strategic opportunities that lie ahead. Market players have shown a keen understanding of the multifaceted segmentation aspects-ranging from treatment types to drug formulations and distribution channels-demonstrating an ongoing commitment to meeting the diverse needs of patients across different settings.

The analysis underscores the importance of aligning product development with emerging trends, regulatory reforms, and evolving patient behaviors. Regional market disparities further emphasize the need for customized strategies that cater to local market demands while maintaining a global perspective. The collaborative efforts among leading companies, combined with strategic investments in innovation, have set the stage for a new era of growth and value creation in the therapeutics space.

Moving forward, a sustained focus on research, technology adoption, and strategic partnerships will be vital. The conclusions drawn in this comprehensive assessment offer actionable insights that industry stakeholders can leverage to navigate the complexities of the anti-obesity therapeutics market while capitalizing on the opportunities that drive enhanced patient outcomes and long-term commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.2. Increasing incidences of obesity and related disorder
      • 5.1.1.3. Enhanced efficacy and safety profiles of newer drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding side effects of anti-obesity therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing investment in R&D propels advancements in cutting-edge anti-obesity drug technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of consistent global policies on obesity treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing preference for anti-obesity therapeutics medication due to its higher efficacy
    • 5.2.2. End-User: Expanding utilization of anti-obesity therapeutics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Obesity Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Bupropion-Naltrexone
    • 6.2.2. Liraglutide
    • 6.2.3. Orlistat
    • 6.2.4. Phentermine-Topiramate
    • 6.2.5. Semaglutide
    • 6.2.6. Tilzepatide
  • 6.3. Treatments
    • 6.3.1. Adjustable Gastric Banding
    • 6.3.2. Endoscopic Sleeve Gastroplasty
    • 6.3.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Over-The-Counter Drugs
  • 7.3. Prescription Drugs

8. Anti-Obesity Therapeutics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Oral Administration
    • 8.2.1. Capsules
    • 8.2.2. Tablets
  • 8.3. Parenteral Administration
    • 8.3.1. Intravenous
    • 8.3.2. Subcutaneous

9. Anti-Obesity Therapeutics Market, by Drug Formulation

  • 9.1. Introduction
  • 9.2. Liquid Dosage Forms
  • 9.3. Semi-Solid Dosage Forms
  • 9.4. Solid Dosage Forms

10. Anti-Obesity Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Anti-Obesity Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospitals & Clinics Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Americas Anti-Obesity Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Anti-Obesity Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Eli Lilly enhances Zepbound accessibility with affordable single-dose vials to address obesity care inequities
    • 15.3.2. Rani Therapeutics and ProGen join forces to co-develop oral obesity treatment
    • 15.3.3. Click Therapeutics boosts obesity and diabetes pipeline with Better Therapeutics Acquisition
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alizyme PLC
  • 2. Amgen Inc.
  • 3. Arena Pharmaceuticals Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Bristol-Myers Squibb Company
  • 6. Currax Pharmaceuticals LLC
  • 7. Eisai Co. Ltd.
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche Ltd
  • 10. FlaxoSithKline plc.
  • 11. GlaxoSmithKline PLC
  • 12. Johnson & Johnson Services Inc.
  • 13. Merck & Co. Inc.
  • 14. Nalpropion Pharmaceuticals Inc.
  • 15. Norgine B.V.
  • 16. Novartis AG
  • 17. Novo Nordisk A/S
  • 18. Orexigen Therapeutics Inc.
  • 19. Pfizer Inc.
  • 20. Rhythm Pharmaceuticals, Inc.
  • 21. Sanofi S.A.
  • 22. SHIONOGI & Co., Ltd.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Vivus Inc.
  • 25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-20